[Tumor necrosis factor and possibilities of correction of its production in patients with suppurative-septic complications in terminal states].
The production of tumor necrosis factor (TNF) by mononuclears was studied in 37 patients after critical states of various origins. A relationship was revealed between the TNF production and the patient's condition severity and the development of pyoseptic complications. Use of thymohexin, a new drug for correction, provided a modulating effect and helped reduce the excessively increased TNF production both in vitro and in the patients with pyoseptic complications.
Leshin
A A
AA
Pisarev
V M
VM
Kremlev
S G
SG
Tutel'ian
A V
AV
Lebedev
V V
VV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D002478:Cells, Cultured; D006801:Humans; D009000:Monocytes / Q000276:immunology; D009842:Oligopeptides / Q000627:therapeutic use*; D018805:Sepsis / Q000276:immunology / Q000628:therapy*; D013492:Suppuration / Q000276:immunology / Q000628:therapy*; D013727:Terminal Care; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D014409:Tumor Necrosis Factor-alpha; C080035:thymohexin
Faktor nekroza opukholi i vozmozhnosti korrektsii ego produktsii u bol'nykh s gnoĭno-septicheskimi oslozhneniiami terminal'nykh sostoianiĭ.